News & Updates

FMT prevents hepatic encephalopathy recurrence in cirrhosis

30 Jun 2025 by

A phase II study has demonstrated the safety of faecal microbiota transplantation (FMT) in patients with cirrhosis treated with lactulose and rifaximin, with no related adverse events (AEs) seen. FMT also results in lower rates of hepatic encephalopathy (HE) recurrence.

FMT prevents hepatic encephalopathy recurrence in cirrhosis

30 Jun 2025

ICIs improve survival in advanced MCC at population level

30 Jun 2025

Treatment of immune checkpoint inhibitors (ICIs) has led to a more than twofold increase in survival for patients with advanced Merkel cell carcinoma (MCC) at the population level, translating to about 220 fewer deaths annually in the US, according to a study.

ICIs improve survival in advanced MCC at population level

30 Jun 2025

Novel GLP-1/GIP formula finishes strong in phase II obesity, T2D trial

30 Jun 2025 by

In part 1 (dose ranging with and without dose escalation) of the phase II MariTide study, significant weight reduction and robust glycaemic improvement were achieved with maridebart cafraglutide (MariTide) – the first, long-acting, GIPR* antagonist and GLP-1R** agonist – in individuals with obesity or overweight and type 2 diabetes (T2D).

Novel GLP-1/GIP formula finishes strong in phase II obesity, T2D trial

30 Jun 2025

Ecnoglutide serves up weight-loss benefit for nondiabetic adults with overweight, obesity

30 Jun 2025

Treatment with the novel cyclic adenosine monophosphate (cAMP)-biased GLP-1 receptor agonist ecnoglutide for weight management is safe and results in substantial and sustained weight loss in adults with obesity or overweight but without diabetes, according to a phase III study.

Ecnoglutide serves up weight-loss benefit for nondiabetic adults with overweight, obesity

30 Jun 2025

Zongertinib shows antitumour activity in previously treated HER2-mutant NSCLC

29 Jun 2025 by

The oral, irreversible, HER2-selective tyrosine kinase inhibitor (TKI) zongertinib confers clinically meaningful benefit to patients with previously treated HER2-mutant nonsmall cell lung cancer (NSCLC), including those with brain metastases, while having a manageable safety profile, according to the phase 1A/1B Beamion LUNG-1 trial.

Zongertinib shows antitumour activity in previously treated HER2-mutant NSCLC

29 Jun 2025

Early HCQ treatment prevents progression of CLE to SLE

29 Jun 2025

Early initiation of hydroxychloroquine (HCQ) protects patients with cutaneous lupus erythematosus (CLE) from progressing to systemic lupus erythematosus (SLE), a recent study has shown.

Early HCQ treatment prevents progression of CLE to SLE

29 Jun 2025

Inclisiran confers LDL–C-lowering benefit in adolescents with HoFH

29 Jun 2025

In adolescents with homozygous familial hypercholesterolemia (HoFH), treatment with inclisiran appears to be safe and efficacious for reducing low-density lipoprotein cholesterol (LDL-C) levels, according to the results of the first part of the phase III ORION-13* trial.

Inclisiran confers LDL–C-lowering benefit in adolescents with HoFH

29 Jun 2025

Infant psychomotor development not harmed by biologic exposure in utero, during breastfeeding

28 Jun 2025

Exposure to biologics for inflammatory bowel disease (IBD) in utero or during breastfeeding does not appear to impair psychomotor development in infants, according to a study.

Infant psychomotor development not harmed by biologic exposure in utero, during breastfeeding

28 Jun 2025

Music therapy provides valuable support in gynaecologic cancer patients in palliative care in SG

28 Jun 2025 by

For women with gynaecologic cancer undergoing inpatient palliative care in Singapore, music therapy helps create a comfortable space to disengage from difficult realities, celebrate life, and process grief and other challenging emotions, as shown in a qualitative study.

Music therapy provides valuable support in gynaecologic cancer patients in palliative care in SG

28 Jun 2025

MMP7 predicts progression, death in antifibrotic-treated IPF

28 Jun 2025 by

Higher levels of matrix metalloprotease 7 (MMP7) pretreatment are predictive of 12-month progression and mortality among patients with idiopathic pulmonary fibrosis (IPF) who have been treated with antifibrotics, reveals a recent study.

MMP7 predicts progression, death in antifibrotic-treated IPF

28 Jun 2025

News & Updates

Filter by Specialty:

Specialty:

FMT prevents hepatic encephalopathy recurrence in cirrhosis

FMT prevents hepatic encephalopathy recurrence in cirrhosis

ICIs improve survival in advanced MCC at population level

ICIs improve survival in advanced MCC at population level

Novel GLP-1/GIP formula finishes strong in phase II obesity, T2D trial

Novel GLP-1/GIP formula finishes strong in phase II obesity, T2D trial

Ecnoglutide serves up weight-loss benefit for nondiabetic adults with overweight, obesity

Ecnoglutide serves up weight-loss benefit for nondiabetic adults with overweight, obesity

Zongertinib shows antitumour activity in previously treated HER2-mutant NSCLC

Zongertinib shows antitumour activity in previously treated HER2-mutant NSCLC

Early HCQ treatment prevents progression of CLE to SLE

Early HCQ treatment prevents progression of CLE to SLE

Inclisiran confers LDL–C-lowering benefit in adolescents with HoFH

Inclisiran confers LDL–C-lowering benefit in adolescents with HoFH

Infant psychomotor development not harmed by biologic exposure in utero, during breastfeeding

Infant psychomotor development not harmed by biologic exposure in utero, during breastfeeding

Music therapy provides valuable support in gynaecologic cancer patients in palliative care in SG

Music therapy provides valuable support in gynaecologic cancer patients in palliative care in SG

MMP7 predicts progression, death in antifibrotic-treated IPF

MMP7 predicts progression, death in antifibrotic-treated IPF